Old drugs, new purpose: Retooling existing drugs for optimized treatment of resistant tuberculosis

Clinical Infectious Diseases

Volumn 55, Issue 4, 2012, Pages 572-581

  Dooley, Kelly E ^a   Mitnick, Carole D ^b   DeGroote, Mary Ann ^c   Obuku, Ekwaro ^d,e   Belitsky, Vera ^f   Hamilton, Carol D ^g   Makhene, Mamodikoe ^h   Shah, Sarita ⁱ   Brust, James C M ⁱ   Durakovic, Nadza ^f   Nuermberger, Eric ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Department of Environmental and Radiological Health Sciences   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^f PARTNERS IN HEALTH   (United States)

^g Health and Development Sciences   (United States)

^h NATIONAL INSTITUTES OF HEALTH   (United States)

ⁱ ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CAPREOMYCIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; TERIZIDONE;

CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; DRUG ACTIVATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESISTANT TUBERCULOSIS; HUMAN; IN VITRO STUDY; MYCOBACTERIUM TUBERCULOSIS; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTITUBERCULAR AGENTS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84864425173     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis487     Document Type: Review

References (45)

1. World Health Organization. Global tuberculosis control: WHO report 2011, WHO Press, World Health Organization, Geneva, Switzerland; 2011.
2. Shi W, Zhang X, Jiang X, et al. Pyrazinamide inhibits trans-Translation in Mycobacterium tuberculosis. Science 2011; 333:1630-2.
3. Ahmad Z, Fraig MM, Bisson GP, Nuermberger EL, Grosset JH, Karakousis PC. Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis. Antimicrob Agents Chemother 2011; 55:1527-32.
4. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999; 3:S231-79.
5. Jindani A, Dore CJ, Mitchison DA. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med 2003; 167:1348-54.
6. Mphahlele M, Syre H, Valvatne H, et al. Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates. J Clin Microbiol 2008; 46:3459-64.
7. Starks AM, Gumusboga A, Plikaytis BB, Shinnick TM, Posey JE. Mutations at embB codon 306 are an important molecular indicator of ethambutol resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2009; 53:1061-6.
8. Hillemann D, Rusch-Gerdes S, Richter E. Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2009; 47:1767-72.
9. Grumbach F. Activite antituberculeuse chez la souris, de l'ethambutol en association avec l'isoniazide ou l'etionamide. Ann Inst Pasteur 1966; 110:69.
10. Radenbach KL. Minimum daily efficient dose of ethambutol: general review. Bull Int Union Tuberc 1973; 48:106-11.
11. Pyle MM. Ethambutol in the retreatment and primary treatment of tuberculosis: a four-year clinical investigation. Ann N Y Acad Sci 1966; 135:835-45.
12. Griffith DE, Brown-Elliott BA, Shepherd S, McLarty J, Griffith L, Wallace RJ Jr. Ethambutol ocular toxicity in treatment regimens for Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2005; 172:250-3.
13. Schaaf HS, Victor TC, Venter A, et al. Ethionamide cross- And coresistance in children with isoniazid-resistant tuberculosis. Int J Tuberc Lung Dis 2009; 13:1355-9.
14. Cynamon MH, Zhang Y, Harpster T, Cheng S, DeStefano MS. Highdose isoniazid therapy for isoniazid-resistant murine Mycobacterium tuberculosis infection. Antimicrob Agents Chemother 1999; 43:2922-4.
15. Parkin DP, Vandenplas S, Botha FJ, et al. Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. Am J Respir Crit Care Med 1997; 155:1717-22.
16. Donald PR, Sirgel FA, Botha FJ, et al. The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis. Am J Respir Crit Care Med 1997; 156:895-900.
17. Katiyar SK, Bihari S, Prakash S, Mamtani M, Kulkarni H. A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrugresistant tuberculosis. Int J Tuberc Lung Dis 2008; 12:139-45.
18. Yoshida S, Suzuki K, Iwamoto T, et al. Comparison of rifabutin susceptibility and rpoB mutations in multi-drug-resistant Mycobacterium tuberculosis strains by DNA sequencing and the line probe assay. J Infect Chemother 2010; 16:360-3.
19. Kelly BP, Furney SK, Jessen MT, Orme IM. Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1996; 40:2809-12.
20. Chan SL, Yew WW, Ma WK, et al. The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosis. Tuber Lung Dis 1992; 73:33-8.
21. Davies G, Cerri S, Richeldi L. Rifabutin for treating pulmonary tuberculosis. Cochrane Database Syst Rev 2007: CD005159.
22. Sanders WE Jr, Hartwig C, Schneider N, Cacciatore R, Valdez H. Activity of amikacin against mycobacteria in vitro and in murine tuberculosis. Tubercle 1982; 63:201-8.
23. Donald PR, Sirgel FA, Venter A, et al. The early bactericidal activity of amikacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2001; 5:533-8.
24. Chan ED, Strand MJ, Iseman MD. Multidrug-resistant tuberculosis (TB) resistant to fluoroquinolones and streptomycin but susceptible to second-line injection therapy has a better prognosis than extensively drug-resistant TB. Clin Infect Dis 2009; 48:e50-2.
25. Kim DH, Kim HJ, Park SK, et al. Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182:113-9.
26. Peloquin CA, Berning SE, Nitta AT, et al. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis 2004; 38:1538-44.
27. Heifets L, Simon J, Pham V. Capreomycin is active against nonreplicating M. tuberculosis. Ann Clin Microbiol Antimicrob 2005; 4:6.
28. Klemens SP, DeStefano MS, Cynamon MH. Therapy of multidrugresistant tuberculosis: lessons from studies with mice. Antimicrob Agents Chemother 1993; 37:2344-7.
29. Popplewell AG, Miller JD, Greene ME, Landwehr A. Capreomycin in original treatment cases of pulmonary tuberculosis. Ann N Y Acad Sci 1966; 135:989-1005.
30. Grumbach F. [The treatment of experimental tuberculosis in mice by the association of isoniazid and ethionamide in different doses: application of the results to clinical posology]. Rev Tuberc Pneumol (Paris) 1961; 25:1365-85.
31. Angel JH, Bhatia AL, Devadatta S, et al. A controlled comparison of cycloserine plus ethionamide with cycloserine plus thiacetazone in patients with active pulmonary tuberculosis despite prolonged previous chemotherapy. Tubercle 1963; 44:215-24.
32. Zhu M, Namdar R, Stambaugh JJ, et al. Population pharmacokinetics of ethionamide in patients with tuberculosis. Tuberculosis (Edinb) 2002; 82:91-6.
33. Mathys V, Wintjens R, Lefevre P, et al. Molecular genetics of paraaminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2009; 53:2100-9.
34. Karlson AG, Gainer JH, Feldman WH. The effect of dihydrostreptomycin para-aminosalicylate on experimental tuberculosis in guinea pigs. Am Rev Tuberc 1950; 62:149-55.
35. Peloquin CA, Henshaw TL, Huitt GA, Berning SE, Nitta AT, James GT. Pharmacokinetic evaluation of para-aminosalicylic acid granules. Pharmacotherapy 1994; 14:40-6.
36. PARA-AMINOSALICYLIC acid treatment in pulmonary tuberculosis. Am Rev Tuberc 1950; 61:597-612.
37. Kam KM, Sloutsky A, Yip CW, et al. Determination of critical concentrations of second-line anti-Tuberculosis drugs with clinical and microbiological relevance. Int J Tuberc Lung Dis 2010; 14: 282-8.
38. Conzelman GM Jr, Jones RK. On the physiologic disposition of cycloserine in experimental animals. Am Rev Tuberc 1956; 74:802-6.
39. Wolinsky E, Steenken W Jr. Cycloserine alone and in combination with other drugs in experimental guinea pig tuberculosis. Am Rev Tuberc 1957; 75:510-3.
40. Epstein IG, Nair KG, Boyd LJ, Auspitz P. Cycloserine-isoniazid combination therapy in virgin cases of pulmonary tuberculosis. Dis Chest 1958; 33:371-81.
41. Falzon D, Jaramillo E, Schunemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38:516-28.
42. Fauci AS. Multidrug-resistant and extensively drug-resistant tuberculosis: the National Institute of Allergy and Infectious Diseases Research agenda and recommendations for priority research. J Infect Dis 2008; 197:1493-8.
43. Mitnick CD, Castro KG, Harrington M, Sacks LV, Burman W. Randomized trials to optimize treatment of multidrug-resistant tuberculosis. PLoS Med 2007; 4:e292.
44. Center for Global Health Policy. A project of the Infectious Diseases Society of America and the HIV Medicine Association. Published by Infectious Diseases Society of America, Arlington, VA, 2010.
45. Van Deun A, Maug AK, Salim MA, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182:684-92.